


# Louis Lasagna Library of Drug Development Science and Policy

*A unique and enduring resource...*



Tufts Center for the  
Study of Drug Development

TUFTS UNIVERSITY



## Dr. Louis Lasagna (1923-2003)

*Preeminent physician, scholar and visionary*

Often considered the founder of the field of clinical pharmacology, Dr. Lasagna was one of the first to study and describe the concept of the placebo response. In 1964, he wrote a modernized version of the Hippocratic Oath, emphasizing a holistic and compassionate approach to medicine. He greatly influenced how clinical trials are currently designed and conducted. During his lifetime, Dr. Lasagna personally influenced the lives of thousands of individuals around the world. His legacy continues to this day.

In 1976, Dr. Lasagna founded the Center for the Study of Drug Development, an academic-based research center whose goal it was to provide scholarly analyses and interpretation to raise the intellectual level of debate on questions of public policy, and improve the quality and efficiency of the drug development process. Today, Tufts CSDD remains true to Dr. Lasagna's vision.

Tufts CSDD's library was established to serve as an important resource for research, to be a repository for relevant literature, and to provide access to all. The library was re-named the Louis Lasagna Library of Drug Development Science and Policy in 2004.

## Supporting the Louis Lasagna Library

Your tax-deductible contribution to the Louis Lasagna Library will help fund ongoing activities and new initiatives including:

- Maintaining the Library's role as a unique and enduring resource for both print and electronic media on pharmaceutical development and regulation.
- Developing a web-based state of the art bibliography.
- Making library materials more accessible to a global audience.
- Providing information and research assistance to industry professionals, regulators, policy makers, journalists, academic scholars, and the general public.
- Cataloging Dr. Louis Lasagna's personal book collection, which includes several hundred volumes that are of historical significance to the study of clinical pharmacology, and to which Dr. Lasagna attached great personal importance throughout his lifetime.



**Sandra Peters, MLIS**  
**Library Director**

***Your contribution to the Louis Lasagna Library Fund is critical to our maintaining a world-class resource, with knowledgeable and professional staff serving all those with an interest in the field of bio-innovation.***

# HOW TO SUPPORT THE LIBRARY

*Donate online at...*

[http://csdd.tufts.edu/library/make\\_donation](http://csdd.tufts.edu/library/make_donation)

*...or use the form below*

Name \_\_\_\_\_

Organization \_\_\_\_\_

Address \_\_\_\_\_

Phone \_\_\_\_\_

Email \_\_\_\_\_

**Yes! I support the unique mission of the Louis Lasagna Library. Please accept my donation in the amount of:**

\$50       \$100       \$250       \$500

\$1000       \$5,000       Other \$ \_\_\_\_\_

I would prefer that this contribution and/or my name be kept confidential.

**Please make check payable to *Trustees of Tufts College* and send to:**

Attn: Sandra Peters, Library Director  
Tufts Center for the Study of Drug Development  
Tufts University  
75 Kneeland St., Suite 1100  
Boston, MA 02111, USA

If you have questions or are interested in donating by installments or planned giving, please contact Sandra Peters at [sandra.peters@tufts.edu](mailto:sandra.peters@tufts.edu)

*Tufts CSDD is a 501(c)3 tax-exempt charitable organization, Tax ID No.04-2103634, and contributions are tax deductible to the full extent permitted by law.*



**Your donation to the Louis Lasagna Library Fund will help sustain our effort to collect, maintain, and disseminate information crucial to key stakeholders involved in the development and regulation of new therapeutics.**



**Tufts Center for the  
Study of Drug Development**

**TUFTS UNIVERSITY**



## **Did you know that the Louis Lasagna Library of Drug Development Science and Policy is...**

- Where a researcher may learn which Alzheimer's drugs are in Phase 3 development...
- Where a journalist working under a tight deadline can obtain accurate information on cancer drug success rates...
- Where an industry professional can gather information on how to make clinical trials more efficient...
- Where a policy maker can find out how quickly patients can gain access to newly approved drugs for rare diseases?

*Last year, the Louis Lasagna Library responded to over 1,000 information requests from individuals in industry, regulatory agencies worldwide, contract research organizations, academic institutions, patient groups, the media, investment companies, the U.S. Congress, the U.S. Department of Defense and many more.*

**The Library needs your help to continue this unique and important work.**

*For more information, visit the Louis Lasagna Library online at <http://csdd.tufts.edu/library>*